Please Wait.....
Report
Global Laboratory-Developed Tests (LDTs) Market - Industry Trends and Forecast to 2030
Market Report I 2023-06-01 I 630 Pages I Data Bridge Market Research
The Global Laboratory-Developed Tests (LDTs) Market is expected to reach USD 41,521.83 Million by 2030 from USD 18,411.29 Million in 2022, growing at a CAGR of 10.7% during the forecast period of 2023 to 2030.
Market Segmentation
Global Laboratory-Developed Tests (LDTs) Market, By Test Type (Clinical Chemistry and Immunology, Critical Care, Hematology, Molecular Diagnostics, Microbiology, and Other Test), Product Type (Consumables, Analyzers and Instruments, and Accessories), Sample Type (Blood, Urine, Tissue, Cerebrospinal Fluid (CSF), and Others), Therapeutic Area (Infections, Genetic Disorders, Oncology/Cancer, Autoimmune Disease, Urology, Gynecology, and Others), Gender (Male, and Female), Age Group (Geriatrics, Adult, and Pediatric), End Users (Hospital-Based Labs, Stand-Alone Labs, Diagnostic Chains, Academic Institutes, Clinical Research Organizations, Specialty Diagnostic Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, and Others), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2030
Overview of Global Laboratory-Developed Tests (LDTs) Market Dynamics
Drivers
- Increasing demand for personalized medicines
- Advancements in molecular diagnostics
Restraint
- Stringent quality control and standardization for LDTs
Opportunity
- Increasing demand for precision medicine and targeted therapy
Market Players
Some of the major market players operating in the global Laboratory-Developed Tests (LDTs) market are:
- F. Hoffmann-La Roche Ltd
- bioMerieux, Inc.
- Sysmex Corporation
- Biomerica, Inc.
- Bio-Rad Laboratories, Inc.
- Abbott
- Siemens Medical Solutions USA, Inc.
- Quest Diagnostics Incorporated
- QIAGEN
- Eurofins Scientific
- Biodesix.
- Hologic, Inc.
- Guardant Health
- OPKO Health, Inc.
- BD
- Beckman Coulter, Inc.
- NeoGenomics Laboratories.
- Seegene Inc.
- Ambry Genetics
- BGI
- 23andMe, Inc.
- Milab Scientific
- Admera Health
- Agendia
TABLE OF CONTENTS
1 INTRODUCTION 67
1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW OF THE GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET 67
1.4 CURRENCY AND PRICING 69
1.5 LIMITATIONS 69
1.6 MARKETS COVERED 69
2 MARKET SEGMENTATION 74
2.1 MARKETS COVERED 74
2.2 GEOGRAPHICAL SCOPE 75
2.3 YEARS CONSIDERED FOR THE STUDY 76
2.4 DBMR TRIPOD DATA VALIDATION MODEL 77
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 80
2.6 MULTIVARIATE MODELLING 81
2.7 TEST TYPE SEGMENT LIFELINE CURVE 81
2.8 MARKET END USER COVERAGE GRID 82
2.9 DBMR MARKET POSITION GRID 83
2.10 VENDOR SHARE ANALYSIS 84
2.11 SECONDARY SOURCES 85
2.12 ASSUMPTIONS 85
3 EXECUTIVE SUMMARY 86
4 PREMIUM INSIGHTS 89
4.1 PESTEL ANALYSIS 92
4.2 PORTER'S FIVE FORCES MODEL 93
5 INDUSTRY INSIGHTS 94
6 NUMBER OF LABS 96
6.1 NUMBER OF LABS IN MIDDLE EASTERN COUNTRIES 96
6.2 NUMBER OF LABS IN EUROPE 96
7 REGULATIONS OF THE GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET 98
7.1 U.S. 98
7.2 EUROPE 98
7.3 SINGAPORE 99
7.4 CHINA 99
7.5 SOUTH AFRICA 100
8 MARKET OVERVIEW 101
8.1 DRIVERS 103
8.1.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 103
8.1.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS 103
8.1.3 GROWING PREVALENCE OF CHRONIC DISEASES 103
8.1.4 INCREASING AWARENESS AND ACCEPTANCE TOWARDS THE ASSISTANCES OF LDTS 104
8.2 RESTRAINTS 104
8.2.1 STRINGENT QUALITY CONTROL AND STANDARDIZATION FOR LDTS 104
8.2.2 STRICT REGULATORY GUIDELINES REGARDING LDTS 105
8.3 OPPORTUNITIES 105
8.3.1 INCREASING DEMAND FOR PRECISION MEDICINE AND TARGETED THERAPY 105
8.3.2 ENHANCED HEALTHCARE SUBSTRUCTURE 106
8.4 CHALLENGES 106
8.4.1 DEPRIVED DATA INTERPRETATION AND INTEGRATION 106
8.4.2 COMPLEX LABORATORY PROCESSES 107
9 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE 108
9.1 OVERVIEW 109
9.2 CLINICAL CHEMISTRY AND IMMUNOLOGY 112
9.2.1 GLUCOSE 113
9.2.1.1 GLUCOSE CHALLENGE TEST 113
9.2.1.2 ORAL GLUCOSE TOLERANCE TEST (OGTT) 113
9.2.2 PROTHROMBIN 114
9.2.3 METABOLIC PANEL 114
9.2.3.1 BASIC 114
9.2.3.2 COMPREHENSIVE 114
9.2.4 LIPID PANEL 114
9.2.5 LIVER PANEL 114
9.2.5.1 ALP TEST (ALKALINE PHOSPHATE) 115
9.2.5.2 ALT TEST (ALKALINE TRANSMINASE) 115
9.2.5.3 AST TEST (ASPARTATE AMINOTRANSFERASE) 115
9.2.5.4 GAMMA-GLUTAMYL TRANSFERASE (GGT) TEST 115
9.2.6 THYROID STIMULATING HORMONE 115
9.2.7 URINALYSIS 115
9.2.7.1 RED BLOOD CELL URINE TEST 116
9.2.7.2 GLUCOSE URINE TEST 116
9.2.7.3 PROTEIN URINE TEST 116
9.2.7.4 URINE PH LEVEL 116
9.2.7.5 KETONES URINE TEST 116
9.2.7.6 BILIBURIN URINE TEST 116
9.2.7.7 URINE SPECIFIC GRAVITY TEST 117
9.2.8 OTHERS 117
9.3 CRITICAL CARE 117
9.3.1 CARBOXYHAEMOGLOBIN TEST 118
9.3.2 PH TEST 118
9.3.3 POTASSIUM TEST 118
9.3.4 SODIUM TEST 118
9.3.5 METHEMOGLOBIN TEST 118
9.3.6 LACTATE TEST 118
9.3.7 OTHERS 119
9.4 HAEMATOLOGY 119
9.4.1 COMPLETE BLOOD COUNT (CBC) 120
9.4.1.1 WHITE BLOOD CELL COUNT (WBC) 120
9.4.1.2 RED BLOOD CELL COUNT (RBC) 120
9.4.2 PLATELET COUNT 120
9.4.3 BLOOD PROTEIN TESTING 121
9.4.4 OTHERS 121
9.5 MOLECULAR DIAGNOSTIC 121
9.5.1 SAMPLE TYPE 122
9.5.1.1 BLOOD 122
9.5.1.2 URINE 122
9.5.1.3 TISSUE 122
9.5.1.4 CEREBROSPINAL FLUID (CSF) 122
9.5.1.5 OTHERS 122
9.5.2 THERAPEUTIC AREA 122
9.5.2.1 INFECTIONS 123
9.5.2.2 GENETIC DISORDERS 123
9.5.2.3 ONCOLOGY/CANCER 123
9.5.2.4 AUTOIMMUNE DISEASE 123
9.5.2.5 UROLOGY 123
9.5.2.6 GYNECOLOGY 123
9.5.2.7 OTHERS 123
9.5.3 TECHNOLOGY 124
9.5.3.1 POLYMERASE CHAIN REACTION (PCR) 124
9.5.3.2 NEXT-GENERATION SEQUENCING (NGS) 124
9.5.3.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 124
9.5.3.4 SANGER SEQUENCING 124
9.5.3.5 MICROARRAYS 124
9.5.3.6 MASS SPECTROMETRY 125
9.5.3.7 ISOTHERMAL AMPLIFICATION 125
9.5.4 END USER 125
9.5.4.1 HOSPITAL-BASED LABS 125
9.5.4.2 STAND-ALONE LABS 125
9.5.4.3 DIAGNOSTIC CHAINS 125
9.5.4.4 ACADEMIC INSTITUTES 126
9.5.4.5 CLINICAL RESEARCH ORGANIZATIONS 126
9.5.4.6 SPECIALTY DIAGNOSTIC CENTERS 126
9.5.4.7 OTHERS 126
9.6 MICROBIOLOGY 126
9.6.1 MICROSCOPY 127
9.6.2 CULTURE 127
9.6.3 ANTIMICROBIAL SUSCEPTIBILITY TEST 127
9.6.4 OTHERS 127
9.7 OTHER TEST 128
9.7.1 DRUGS OF ABUSE TESTING 129
9.7.2 HEPATITIS 129
9.7.3 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) 129
9.7.4 MALARIA 129
9.7.5 TUBERCULOSIS 129
9.7.6 HUMAN PAPILLOMAVIRUS (HPV) 129
9.7.7 OTHERS 130
10 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE 131
10.1 OVERVIEW 132
10.2 CONSUMABLES 135
10.2.1 PANELS 135
10.2.2 REAGENT AND KITS 136
10.2.3 OTHERS 136
10.3 ANALYZERS AND INSTRUMENTS 136
10.3.1 FULLY-AUTOMATED INSTRUMENTS 137
10.3.2 SEMI-AUTOMATED INSTRUMENTS 137
10.3.3 OTHERS 137
10.4 ACCESSORIES 137
11 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE 139
11.1 OVERVIEW 140
11.2 BLOOD 143
11.3 URINE 143
11.4 TISSUE 144
11.5 CEREBROSPINAL FLUID (CSF) 144
11.6 OTHERS 145
12 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA 147
12.1 OVERVIEW 148
12.2 INFECTIONS 151
12.2.1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 152
12.2.2 CLOSTRIDIUM DIFFICILE 152
12.2.3 VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 152
12.2.4 CARBAPENEM-RESISTANT BACTERIA 152
12.2.5 FLU 152
12.2.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) 153
12.2.7 CANDIDA 153
12.2.8 TUBERCULOSIS AND DRUG-RESISTANT TBA 153
12.2.9 MENINGITIS 153
12.2.10 GASTROINTESTINAL PANEL TESTING 153
12.2.11 CHLAMYDIA 153
12.2.12 GONORRHEA 153
12.2.13 HIV 153
12.2.14 HEPATITIS B 153
12.2.15 HEPATITIS C 153
12.2.16 OTHER INFECTIOUS DISEASES 153
12.3 GENETIC DISORDERS 154
12.3.1 NEW BORN SCREENING 154
12.3.2 PREDICTIVE AND PRESYMPTOMATIC TESTING 155
12.3.3 OTHER GENETIC TESTING 155
12.4 ONCOLOGY/CANCER 155
12.4.1 BREAST CANCER 156
12.4.2 PROSTATE CANCER 156
12.4.3 COLORECTAL CANCER 156
12.4.4 CERVICAL CANCER 156
12.4.5 KIDNEY CANCER 156
12.4.6 LIVER CANCER 156
12.4.7 BLOOD CANCER 156
12.4.8 LUNG CANCER 157
12.4.9 OTHER CANCER 157
12.5 AUTOIMMUNE DISEASE 157
12.6 UROLOGY 157
12.7 GYNECOLOGY 158
12.8 OTHERS 159
13 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER 160
13.1 OVERVIEW 161
13.2 MALE 164
13.3 FEMALE 164
14 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP 166
14.1 OVERVIEW 167
14.2 GERIATRICS 170
14.3 ADULT 170
14.4 PEDIATRICS 171
15 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER 172
15.1 OVERVIEW 173
15.2 HOSPITAL-BASED LABS 176
15.3 STAND -ALONE LABS 176
15.4 DIAGNOSTIC CHAINS 177
15.5 ACADEMIC INSTITUTES 178
15.6 CLINICAL RESEARCH ORGANISTAION 178
15.7 SPECIALTY DIAGNOSTIC 179
15.8 OTHERS 180
16 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL 181
16.1 OVERVIEW 182
16.2 DIRECT TENDER 185
16.3 RETAIL SALES 185
16.4 THIRD PARTY DISTRIBUTORS 186
16.5 OTHERS 187
17 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION 188
17.1 OVERVIEW 189
17.2 NORTH AMERICA 195
17.2.1 U.S. 210
17.2.2 CANADA 219
17.2.3 MEXICO 228
17.3 EUROPE 237
17.3.1 GERMANY 252
17.3.2 U.K. 261
17.3.3 FRANCE 270
17.3.4 ITALY 279
17.3.5 RUSSIA 288
17.3.6 SPAIN 297
17.3.7 NETHERLANDS 306
17.3.8 SWITZERLAND 315
17.3.9 BELGIUM 324
17.3.10 TURKEY 333
17.3.11 REST OF EUROPE 342
17.4 ASIA PACIFIC 343
17.4.1 CHINA 357
17.4.2 JAPAN 366
17.4.3 INDIA 375
17.4.4 AUSTRALIA 384
17.4.5 SOUTH KOREA 393
17.4.6 INDONESIA 402
17.4.7 PHILIPPINES 411
17.4.8 THAILAND 420
17.4.9 MALAYSIA 429
17.4.10 SINGAPORE 438
17.4.11 REST OF ASIA-PACIFIC 447
17.5 SOUTH AMERICA 448
17.5.1 BRAZIL 466
17.5.2 ARGENTINA 479
17.5.3 REST OF SOUTH AMERICA 492
17.6 MIDDLE EAST AND AFRICA 493
17.6.1 SAUDI ARABIA 511
17.6.2 SOUTH AFRICA 524
17.6.3 U.A.E 537
17.6.4 EGYPT 550
17.6.5 ISRAEL 563
17.6.6 REST OF MIDDLE EAST AND AFRICA 576
18 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, COMPANY LANDSCAPE 577
18.1 COMPANY SHARE ANALYSIS: GLOBAL 577
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 578
18.3 COMPANY SHARE ANALYSIS: EUROPE 579
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 580
19 COMPANY PROFILES 581
19.1 F. HOFFMANN-LA ROCHE LTD. 581
19.1.1 COMPANY SNAPSHOT 581
19.1.2 REVENUE ANALYSIS 581
19.1.3 COMPANY SHARE ANALYSIS 582
19.1.4 PRODUCT PORTFOLIO 582
19.1.5 RECENT DEVELOPMENT 582
19.2 BIOMERIEUX 583
19.2.1 COMPANY SNAPSHOT 583
19.2.2 REVENUE ANALYSIS 583
19.2.3 COMPANY SHARE ANALYSIS 584
19.2.4 PRODUCT PORTFOLIO 584
19.2.5 RECENT DEVELOPMENTS 584
19.3 SYSMEX CORPORATION 585
19.3.1 COMPANY SNAPSHOT 585
19.3.2 REVENUE ANALYSIS 585
19.3.3 COMPANY SHARE ANALYSIS 586
19.3.4 PRODUCT PORTFOLIO 586
19.3.5 RECENT DEVELOPMENT 586
19.4 BIOMERICA. 587
19.4.1 COMPANY SNAPSHOT 587
19.4.2 REVENUE ANALYSIS 587
19.4.3 COMPANY SHARE ANALYSIS 588
19.4.4 PRODUCT PORTFOLIO 588
19.4.5 RECENT DEVELOPMENT 588
19.5 BIO-RAD LABORATORIES, INC 589
19.5.1 COMPANY SNAPSHOT 589
19.5.2 REVENUE ANALYSIS 589
19.5.3 COMPANY SHARE ANALYSIS 590
19.5.4 PRODUCT PORTFOLIO 590
19.5.5 RECENT DEVELOPMENT 590
19.6 23ANDME, INC. 591
19.6.1 COMPANY SNAPSHOT 591
19.6.2 REVENUE ANALYSIS 591
19.6.3 PRODUCT PORTFOLIO 592
19.6.4 RECENT DEVELOPMENTS 592
19.7 ABBOTT 593
19.7.1 COMPANY SNAPSHOT 593
19.7.2 REVENUE ANALYSIS 593
19.7.3 PRODUCT PORTFOLIO 594
19.7.4 RECENT DEVELOPMENT 594
19.8 ADMERA HEALTH 595
19.8.1 COMPANY SNAPSHOT 595
19.8.2 PRODUCT PORTFOLIO 595
19.8.3 RECENT DEVELOPMENT 595
19.9 AGENDIA. 596
19.9.1 COMPANY SNAPSHOT 596
19.9.2 PRODUCT PORTFOLIO 596
19.9.3 RECENT DEVELOPMENT 596
19.10 AMBRY GENETICS 597
19.10.1 COMPANY SNAPSHOT 597
19.10.2 PRODUCT PORTFOLIO 597
19.10.3 RECENT DEVELOPMENT 598
19.11 BD 599
19.11.1 COMPANY SNAPSHOT 599
19.11.2 REVENUE ANALYSIS 599
19.11.3 PRODUCT PORTFOLIO 600
19.11.4 RECENT DEVELOPMENTS 600
19.12 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER) 601
19.12.1 COMPANY SNAPSHOT 601
19.12.2 REVENUE ANALYSIS 601
19.12.3 PRODUCT PORTFOLIO 602
19.12.4 RECENT DEVELOPMENTS 602
19.13 BGI. 603
19.13.1 COMPANY SNAPSHOT 603
19.13.2 PRODUCT PORTFOLIO 603
19.13.3 RECENT DEVELOPMENT 604
19.14 BIODESIX. 605
19.14.1 COMPANY SNAPSHOT 605
19.14.2 REVENUE ANALYSIS 605
19.14.3 PRODUCT PORTFOLIO 606
19.14.4 RECENT DEVELOPMENTS 606
19.15 EUROFINS SCIENTIFIC 607
19.15.1 COMPANY SNAPSHOT 607
19.15.2 REVENUE ANALYSIS 607
19.15.3 PRODUCT PORTFOLIO 608
19.15.4 RECENT DEVELOPMENT 608
19.16 GUARDANT HEALTH 609
19.16.1 COMPANY SNAPSHOT 609
19.16.2 REVENUE ANALYSIS 609
19.16.3 PRODUCT PORTFOLIO 610
19.16.4 RECENT DEVELOPMENTS 610
19.17 HOLOGIC, INC. 611
19.17.1 COMPANY SNAPSHOT 611
19.17.2 REVENUE ANALYSIS 611
19.17.3 PRODUCT PORTFOLIO 612
19.17.4 RECENT DEVELOPMENT 612
19.18 MILAB SCIENTIFIC. 613
19.18.1 COMPANY SNAPSHOT 613
19.18.2 PRODUCT PORTFOLIO 613
19.18.3 RECENT DEVELOPMENT 613
19.19 NEOGENOMICS LABORATORIES 614
19.19.1 COMPANY SNAPSHOT 614
19.19.2 REVENUE ANALYSIS 614
19.19.3 PRODUCT PORTFOLIO 615
19.19.4 RECENT DEVELOPMENTS 615
19.20 OPKO HEALTH, INC. 616
19.20.1 COMPANY SNAPSHOT 616
19.20.2 REVENUE ANALYSIS 616
19.20.3 PRODUCT PORTFOLIO 617
19.20.4 RECENT DEVELOPMENT 617
19.21 QIAGEN 618
19.21.1 COMPANY SNAPSHOT 618
19.21.2 REVENUE ANALYSIS 618
19.21.3 PRODUCT PORTFOLIO 619
19.21.4 RECENT DEVELOPMENTS 619
19.22 QUEST DIAGNOSTICS INCORPORATED. 620
19.22.1 COMPANY SNAPSHOT 620
19.22.2 REVENUE ANALYSIS 620
19.22.3 PRODUCT PORTFOLIO 621
19.22.4 RECENT DEVELOPMENTS 621
19.23 SEEGENE INC 622
19.23.1 COMPANY SNAPSHOT 622
19.23.2 REVENUE ANALYSIS 622
19.23.3 PRODUCT PORTFOLIO 623
19.23.4 RECENT DEVELOPMENT 623
19.24 SIEMENS HEALTHCARE GMBH 624
19.24.1 COMPANY SNAPSHOT 624
19.24.2 REVENUE ANALYSIS 624
19.24.3 PRODUCT PORTFOLIO 625
19.24.4 RECENT DEVELOPMENT 625
20 QUESTIONNAIRE 626
21 RELATED REPORTS 630
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security